A groundbreaking clinical trial led by researchers at the Yale School of Medicine has officially launched to investigate whether the anti-inflammatory drug adalimumab can successfully delay or entirely prevent the onset of Parkinson’s disease. Focused on individuals diagnosed with rapid eye movement sleep behavior disorder (RBD)—a condition strongly linked to a significantly elevated risk of developing the neurodegenerative disorder—this study represents a major milestone in preventive neurology.
Spearheaded by Jesse Cedarbaum, MD, professor of neurology, and David Hafler, MD, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale, the clinical trial is the first of its kind to test whether a targeted pharmaceutical intervention can halt or slow down the trajectory of Parkinson’s disease before clinical motor symptoms ever materialize.
For decades, medical science has understood that the hallmark motor problems of Parkinson’s disease—such as tremors, rigidity, and slowed movement—are preceded by warning signs that manifest long before formal diagnosis. Among the most reliable early indicators is a parasomnia known as rapid eye movement sleep behavior disorder, in which individuals physically and sometimes violently act out vivid dreams. Clinical statistics show that up to 90% of individuals who present with isolated or idiopathic RBD eventually progress to develop Parkinson’s disease or a related brain disorder characterized by abnormal protein aggregation.
This significant temporal window, which often spans 15 to 20 years between the initial presentation of RBD and the onset of overt motor symptoms, provides an unprecedented window of opportunity for clinical intervention. Investigators at Yale believe that intercepting the underlying disease process during this pre-motor phase could fundamentally alter patient outcomes. Recent research conducted by Yale scientists studying the intersection of RBD and Parkinson’s disease points toward persistent neuroinflammation within the central nervous system as a driving contributor to early disease progression.
To test this hypothesis, the newly launched clinical trial is evaluating adalimumab—widely known by the brand name Humira—which is an established biologic therapy currently prescribed to manage various inflammatory and autoimmune conditions, including rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. The trial, formally titled "An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder" and known by the acronym PRISMS, recently enrolled its first patient and is actively recruiting participants between the ages of 50 and 80 across 15 specialized medical centers throughout the United States and Canada.
According to Dr. Cedarbaum, this initiative marks uncharted territory in the field. This is the first clinical trial of its kind to deploy an immunologically based strategy in an effort to slow or halt the unfolding progression of Parkinson’s disease prior to the appearance of classic motor impairments.
What is REM Sleep Behavior Disorder?
Rapid eye movement sleep represents the distinct phase of the human sleep cycle during which the most vivid and active dreaming takes place. This stage derives its designation from the characteristic eye movements observed behind closed eyelids as sleepers visually track the narrative of their dreams. Under normal physiological conditions, the skeletal musculature remains entirely inactive during this phase because healthy brain networks engage an active paralysis mechanism that inhibits movement from the eyes down. Observers can frequently witness a milder version of this protective physiological dampening in sleeping domestic animals, such as a puppy whose paws twitch or whimper while dreaming as the brain partially suppresses full physical enactment.
In contrast, patients afflicted with rapid eye movement sleep behavior disorder experience a systemic failure of this dream paralysis mechanism. The breakdown of this neurological safeguard places both the affected individuals and their bed partners at substantial risk of physical trauma. Patients may inadvertently propel themselves out of bed, strike out with violent kicks, or punch surrounding objects. Clinical documentation of the disorder also includes instances where sleeping patients execute surprisingly coordinated, calm activities, such as sitting up to mimic drinking coffee or smoking a cigarette while entirely unconscious.
While certain medications, including specific classes of antidepressants, can occasionally trigger RBD, many patients develop the condition spontaneously without an obvious external catalyst. Clinically referred to as idiopathic or isolated RBD, this presentation carries a profoundly elevated prognostic risk for subsequent neurological deterioration, frequently preceding Parkinson’s disease or related synucleinopathies such as dementia with Lewy bodies.
Individuals who seek medical evaluation for newly onset RBD face a sobering cumulative risk, transitioning toward Parkinson’s disease or related disorders at a consistent rate of approximately 6% per year. Because this transition unfolds gradually across a multi-decade timeline, recognizing the syndrome early offers clinicians a critical strategic advantage.
Emerging neuropathological evidence indicates that Parkinson’s disease may originate outside the central nervous system, frequently taking root within the gastrointestinal tract. All human nerve cells natively express a functional protein designated as alpha-synuclein. However, post-mortem examinations of brains from patients who succumbed to Parkinson’s disease consistently reveal dense, abnormal aggregations of these proteins, structurally identified as Lewy bodies. Investigators have similarly identified pathological clumps of alpha-synuclein within the enteric nervous system of the gut, with experimental evidence demonstrating that these protein aggregates can propagate toward the central nervous system via distinct neuroanatomical pathways.
The most prominent neuroanatomical route of transmission is the vagus nerve, which establishes a direct structural bridge between the gastrointestinal tract and the brainstem. Alternatively, pathological protein aggregation can initiate within the olfactory bulb, providing a mechanistic explanation for why many individuals with early-stage Parkinson’s disease report an early loss of their sense of smell.
Upon reaching the brainstem, aggregated alpha-synuclein engages in progressive cell-to-cell propagation, gradually ascending higher into intracranial structures. Among the earliest vulnerable populations encountered by this ascending wave are the precise neural networks responsible for coordinating dream-associated muscle paralysis, directly precipitating the emergence of RBD.
As the pathological aggregation continues its upward migration, it reaches a specialized midbrain structure known as the substantia nigra. Located within the basal ganglia—a complex network of interconnected subcortical nuclei that regulate voluntary motor control—the substantia nigra is responsible for synthesizing and dispatching the neurotransmitter dopamine to adjacent basal ganglia structures. The structural impairment and degeneration of this dopaminergic signaling pathway directly cause the characteristic motor symptoms associated with Parkinson’s disease.
Dr. Cedarbaum uses a mechanical analogy to clarify this neurological architecture, describing the brain’s movement programs as a complex transmission system where the basal ganglia functions as the gearbox. In this physiological framework, dopamine acts essentially as lubricating oil. When pathological alpha-synuclein damages the cellular architecture of the substantia nigra, the region loses its capacity to manufacture adequate dopamine oil, causing movement to become progressively sluggish, rigid, and tremulous.
While contemporary pharmacological interventions, most notably levodopa, remain highly effective at temporarily replenishing dopamine levels and suppressing the visible motor symptoms of Parkinson’s disease, they fundamentally fail to alter the underlying natural history of alpha-synuclein propagation. The protein clumps continue their insidious ascent within the brain over decades, eventually invading cortical regions that govern higher cognitive functions and ultimately inducing dementia. The emergence of RBD serves as a reliable biological alarm bell signaling that this destructive pathological cascade is already actively underway.
Inflammation and Parkinson’s Disease
The accumulation and propagation of alpha-synuclein represent only one dimension of the complex pathology underlying Parkinson’s disease. Dr. Cedarbaum dedicated a substantial portion of his distinguished career as a movement disorder neurologist to discovering therapeutic strategies designed to prevent the progressive apoptosis of dopamine-producing neurons. Nearing retirement, he was approached by Dr. Hafler, a globally recognized authority on multiple sclerosis whose pioneering immunological research generated significant therapeutic breakthroughs for autoimmune diseases, with the shared aspiration of applying analogous investigative frameworks to neurodegeneration.
Recognizing striking clinical and pathophysiological parallels between the early presentation of RBD and the initial phases of multiple sclerosis, the two researchers secured a collaborative grant in 2021 from the Aligning Science Across Parkinson’s (ASAP) network. Their investigative team performed spinal taps on a large, well-characterized cohort comprising participants with RBD, established Parkinson’s disease, and dual diagnoses, alongside healthy control subjects and patients diagnosed with multiple sclerosis.
Subsequent laboratory analyses revealed elevated concentrations of white blood cells within the cerebrospinal fluid of participants presenting with RBD, serving as a direct biochemical indicator of active central nervous system inflammation. Notably, this pronounced inflammatory signature was absent in participants who had already progressed to full Parkinson’s disease, mirroring the natural disease trajectory observed in multiple sclerosis.
According to Dr. Hafler, the parallel is striking. During the early autoimmune phase of multiple sclerosis, clinicians consistently observe white blood cell infiltration within the spinal fluid. However, as the condition advances chronologically, the underlying biological process transitions away from a purely inflammatory state, yielding increasingly prominent neurodegenerative changes.
Advanced single-cell RNA sequencing of the cerebrospinal fluid cells isolated specific cellular subsets in which pro-inflammatory gene transcription was significantly upregulated. These specific cells functioned as cellular receptors for tumor necrosis factor (TNF), a major cytokine known to drive chronic inflammatory activity across several systemic autoimmune diseases, including rheumatoid arthritis, ulcerative colitis, and Crohn’s disease. This discovery provided compelling corroborative evidence that inflammatory mechanisms, specifically pathways mediated by tumor necrosis factor, play a critical causal role during the earliest presymptomatic phases of Parkinson’s disease.
This mechanistic link aligns with epidemiological observations showing that individuals diagnosed with systemic autoimmune disorders like rheumatoid arthritis, Crohn’s disease, and ulcerative colitis face an elevated baseline risk of subsequently developing Parkinson’s disease—an epidemiological vulnerability shared by patients with isolated RBD. Crucially, retrospective data demonstrated that patients treated with adalimumab for their autoimmune conditions experienced a reduction in Parkinson’s disease risk down to baseline population levels. Adalimumab functions as a monoclonal antibody designed to bind directly to soluble and transmembrane tumor necrosis factor in the bloodstream, neutralizing its biological activity and preventing downstream cellular inflammation.
Building upon these converging lines of evidence, the investigative team hypothesized that administering adalimumab might effectively suppress the neuroinflammatory cascades contributing to the pathogenesis of Parkinson’s disease.
Dr. Ronald Postuma, professor of neurology at McGill University and principal investigator for the PRISMS study in Canada, emphasizes the therapeutic rationale, noting that the presence of extensive neuroinflammation early in the disease course suggests that dampening aberrant immune activation could successfully prevent bystander tissue damage, wherein activated immune cells erroneously attack healthy neural architecture.
What is the PRISMS Study?
The PRISMS clinical trial is coordinated through a robust multicenter network, incorporating 14 academic medical centers across the United States—including Yale—and one specialized site in Canada. These institutions form part of the Parkinson Study Group, an established academic consortium that has successfully designed and executed over 100 clinical trials targeting Parkinson’s disease and related movement disorders over the past four decades. Operational coordination for the trial is managed by the Center for Health Technology at the University of Rochester.
To qualify for trial enrollment, prospective candidates must undergo a comprehensive polysomnography, or overnight sleep study, to establish a definitive, objectively confirmed diagnosis of rapid eye movement sleep behavior disorder. To maximize the clinical probability that underlying alpha-synuclein aggregation is driving the observed RBD, researchers screen candidates for hyposmia, defined as a clinically significant reduction or loss of the sense of smell. While definitive confirmation of Lewy body pathology typically requires invasive diagnostic procedures such as lumbar punctures or skin biopsies, clinical validation studies demonstrate that individuals manifesting both RBD and olfactory impairment exhibit at least a 90% probability of harboring underlying alpha-synuclein pathology. Consequently, meeting both criteria is mandatory for trial eligibility.
Upon successful enrollment, participants are randomized to receive either self-administered subcutaneous injections of adalimumab or a matching placebo every two weeks over a continuous two-year treatment period. Throughout the duration of the trial, participants attend approximately nine scheduled visits at their respective clinical research sites. These appointments involve comprehensive health status evaluations, detailed assessments of motor function and cognitive performance, and serial blood draws designed to monitor immune cell function and track circulating biomarkers related to Parkinson’s disease progression. Additionally, approximately half of the cohort is asked to undergo annual lumbar punctures to evaluate longitudinal changes in cerebrospinal fluid composition, specifically monitoring for alterations in alpha-synuclein aggregation dynamics.
Participants also complete an extensive multi-modal neuroimaging protocol on an annual basis. This protocol incorporates two specialized brain scans, including magnetic resonance imaging, designed to evaluate structural integrity and functional impairment within the central dopamine network. A third nuclear imaging scan measures regional cerebral metabolic activity by tracking the uptake of a safe, low-dose radioactive glucose tracer. Because brains of individuals developing Parkinson’s disease exhibit characteristic metabolic abnormalities in specific anatomical regions years before motor symptoms manifest, monitoring these regional energy utilization patterns provides an objective readout of disease trajectory.
If the experimental therapy successfully prevents the progressive deterioration of these metabolic patterns or halts the ongoing loss of dopaminergic signaling, researchers will secure vital biological validation that the therapeutic mechanism is operating as intended, according to Dr. Cedarbaum.
Like all pharmaceutical interventions, adalimumab carries a known safety profile that includes specific risks. Administration of the biologic drug is associated with an increased susceptibility to certain opportunistic infections, notably tuberculosis and viral hepatitis, as well as a marginally elevated risk of specific malignancies and rare neurological complications exhibiting clinical features similar to multiple sclerosis. To prioritize patient safety, the trial protocol mandates rigorous clinical monitoring throughout the study period to promptly identify and manage any potential adverse events.
Current medical therapies available for Parkinson’s disease remain highly efficient at managing clinical symptoms once they emerge, yet they consistently fail to alter the inexorable progression of the underlying neuropathology. The investigative team expresses considerable enthusiasm not only for identifying a disease-modifying treatment strategy that directly targets fundamental pathological mechanisms, but also for deploying this intervention during the crucial pre-motor window.
Comparing the initiative to breakthroughs achieved in a related neurological discipline, Dr. Hafler notes that early intervention in multiple sclerosis achieves remarkable efficacy in arresting disease progression, expressing optimism that the medical community can achieve an analogous paradigm shift in neurodegenerative research through timely recognition and early therapeutic deployment.
The research team anticipates that the PRISMS study will catalyze broader scientific inquiry and inspire future clinical trials evaluating alternative pharmacological agents for Parkinson’s disease prevention. Investigators plan to build upon this foundational work by designing subsequent clinical trials exploring other promising molecular candidates. Slowing down the clinical trajectory toward the severe, debilitating stages of the disorder would represent a transformative breakthrough for patient care.
Furthermore, the initiative underscores the critical importance of interdisciplinary cooperation across medical specialties. When movement disorder neurologists forge collaborative partnerships with sleep specialists and immunologists, the medical community opens new frontiers for potential scientific and clinical breakthroughs.
The PRISMS clinical trial is supported by generous research grants provided by the Marcus Foundation and the National Institute on Aging. Comprehensive information regarding trial protocols, specific eligibility criteria, and participating clinical site locations remains publicly accessible via clinicaltrials.gov and through the dedicated study webpage hosted by the Yale School of Medicine.
